Zura Bio Limited Class A Ordinary Shares (ZURA) Stock Price
ZURAStock
$6.32+213.43%52W
Market Cap$605.64M
P/E—
PEG Ratio—
Div yield—
Beta-0.06
ZURA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-9.80%
Price vs S&P 500 (4W)10.67%
VGM Score83.00
ZURA Earnings Surprise History
Q2 25-0.17est. -0.18
Q3 25-0.21est. -0.18
Q4 25-0.49est. -0.15
Q1 26-0.22est. -0.18
Q2 26-0.21est. -0.19
ZURA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.36
4.36
4.36
4.43
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ZURAZura Bio Limited Class A Ordinary Shares | — | — | A | $6.32 |
| AMGNAmgen Inc | C | C | B | $442.24 |
| GILDGilead Sciences Inc | C | B | B | $148.77 |
| MRNAModerna, Inc. Common Stock | D | C | A | $158.83 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1019.49 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $211.38 |
| BIIBBiogen Inc. Common Stock | C | D | B | $220.77 |
| BNTXBioNTech SE American Depositary Share | C | C | B | $114.05 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $153.37 |
| EXELExelixis Inc | C | B | B | $56.72 |
| HALOHalozyme Therapeutics, Inc. | C | B | A | $109.32 |
About Zura Bio Limited Class A Ordinary Shares
Zura Bio Ltd is a clinical-stage immunology company developing novel dual-pathway antibodies to treat autoimmune and inflammatory diseases. The company has three lead programs that have completed Phase I/Ib studies and are advancing to Phase II trials. Its pipeline includes tibulizumab and torudokimab, which are being evaluated for efficacy, safety, and dosing convenience across multiple therapeutic indications.